Terray Therapeutics announced it reached its first discovery milestone under a multi‑target collaboration with Bristol Myers Squibb, validating its Experimentation Meets Machine Intelligence (EMMI) platform. The milestone targets a novel, challenging protein nominated by BMS and demonstrates Terray’s ability to discover small molecules in chemical space not covered by existing datasets. Terray’s approach combines ultraminiaturized binding‑affinity hardware (tArray) with machine intelligence to generate large-scale binding data and guide generative chemistry. The company reports billions of measurements feeding its COATI reasoning model, designed to generalize beyond training data. The deal milestone underscores growing industry interest in integrated hardware‑driven data generation plus AI to overcome generalization limits in molecular discovery and de‑risk early hit finding for difficult targets.